Ksenija Stach: Is This The Future of Lipid-Lowering Lherapy?
Ksenija Stach, Professor of Endocrinology and Diabetology at HMU Health and Medical University, shared a post on LinkedIn:
“Is this the future of lipid-lowering therapy?
Exciting insights from EAS 2026 in Athens:
The presented data on PCSK9 targeting, base editing, and epigenetic approaches demonstrate how rapidly lipid therapy is evolving.
From traditional LDL–C lowering therapies, small molecules, mAbs, and RNAi to potential ‘one-and-done’ treatments, we may be witnessing a true paradigm shift:
- durable LDL-C reduction after a single treatment
- new approaches to improve adherence and persistence
- epigenetic regulation instead of permanent genetic modification
- impressive preclinical and early clinical data
What I found particularly fascinating was the discussion around whether we are moving from chronic treatment strategies toward long-lasting molecular interventions.
At the same time, important questions remain:
- long-term safety
- reversibility
- cost and accessibility
- ethical considerations of genetic interventions
Still, the direction is becoming increasingly clear:
cardiovascular prevention could be fundamentally redefined over the coming years.
What do you think — are we witnessing the beginning of a new era in lipid-lowering therapy?”
Stay updated with Hemostasis Today.
-
Oct 17, 2026, 04:07Weihao Li: Global HEPATIC Registry Findings on Post-Transplant Arterial Thrombosis
-
Oct 17, 2026, 03:56Ghaith Abu-Zeinah: ASH Publishes 2026 Guidelines for Myelofibrosis Management in Blood Advances
-
Oct 17, 2026, 03:48Tristan Siokos: Why Vascular Occlusion Is More Than Just Clots – Breakdown of the 8 Pathways
-
Oct 17, 2026, 02:36Archil Jaliashvili: Oxygen Transport in Capillaries
-
Oct 17, 2026, 02:35Carly Newton: Understanding Access to Red Blood Cell Exchange for People Living With SCD
-
Oct 17, 2026, 02:34Raising Awareness of Blood Clots During and After Pregnancy – Thrombosis UK
-
Oct 17, 2026, 02:33Alaa Salamat: Our Research Accepted for Publication at ASH 2026
-
Oct 17, 2026, 02:32Mohammed Al Sharif: Discussing Factor XIII Testing and Its Clinical Significance
-
Oct 17, 2026, 02:31Joanna Popiolek-Kalisz: Talking about Novel Pharmacotherapy for Hypertension at CV Prevention and Intervention